This site contains promotional content intended for UK Healthcare Professionals and other relevant decision makers | Not a HCP? Visit our  Public Site.

Adverse Event reporting can be found at the bottom of the page | Prescribing Information for the relevant medicine can be found adjacent to the below content and/or in the footer below. 

Cardiovascular
Cardiovascular
Womens Health
Women's Health
two kidneys
Nephrology
Oncology
Oncology
Ophthalmology
Ophthalmology
Respiratory
Respiratory
Bayer for ProfessionalsYour Resource Portal

Cardiovascular Summit 2025 - ATTR-CM Highlights

The Past, Present and Future

CV Summit Banner

Bayer's Cardiovascular Summit took place in London on the 3rd and 4th of October 2025.
Designed to offer education including expert perspectives and discussions on the management of Heart Failure, including differential diagnoses such as Cardiomyopathy and Amyloidosis, with a focus on Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

 

ATTR-CM Key Highlights

Here you can find short videos from our expert speakers, highlighting key points from the sessions discussing ATTR-CM in depth, including; 

  • New developments in the management of ATTR-CM
  • How to manage Heart Failure in patients with ATTR-CM
  • Real-World experience of novel treatments for ATTR-CM, with specific focus on Beyonttra
    ▼
    (Acoramidis)

 

New Developments in the Management of ATTR-CM.

Dr Aldostefano Porcari (3:30 Minutes)

Heart Failure Management in ATTR-CM.

Dr. Jason Dungu (1:35 Minute)

Real World Experience Treating ATTR-CM with Acoramidis.

Prof. Carsten Tschoepe (2:40 Minutes)

Please double click on the video to view it full screen.

BEYONTTRA
▼
(acoramidis) Prescribing Information
.

This promotional meeting was initiated and funded by Bayer UK and is for UK Healthcare professionals only

Find out more about our Expert Speakers

Dr Porcari
Dr Dungu
Prof Tschoepe

    Dr Aldostefano Porcari is a Consultant Cardiologist at the Cardiovascular Department 
    (Azienda Sanitaria Universitaria Giuliano-Isontina, ASUGI), Italy, and a Research 
    Fellow at University College London (UCL), UK. He recently completed a PhD in 
    amyloidosis at UCL’s National Amyloidosis Centre under Prof. Julian D. Gillmore and 
    Prof. Marianna Fontana. His work focuses on early diagnosis, clinical management, 
    treatment and prognostic stratification of amyloidosis - particularly transthyretin (ATTR) 
    cardiomyopathy. Dr Porcari has contributed to studies that have shaped contemporary 
    diagnostic pathways and real-world treatment outcomes, with findings published in 
    leading journals. He has authored more than 135 peer-reviewed papers (including in 
    Circulation, JACC, European Heart Journal, and JAMA Cardiology) and received over 
    20 research prizes, notably the Melvin Judkins Early Career Award (AHA, 2023), the 
    Young Investigator Award Preventive Cardiology (ESC 2022) and Clinical Cardiology 
    (ESC 2025), and the William W. Parmley Young Author Achievement Award (ACC/ 
    JACC, 2025). Current interests include understanding natural history in early disease 
    stages, pragmatic algorithms for stroke prevention, measuring disease-progression, 
    and integrating imaging and genetics into personalised care.

    Dr Dungu is a Consultant Cardiologist at the Essex Cardiothoracic Centre and Honorary Senior Clinical Lecturer at Anglia Ruskin University. He has lead the Essex Inherited 
    Cardiac Conditions (ICC) service since it was established January 2023, and he was 
    the first cardiologist with specialist cardiac MRI training in the Essex region.

    Dr Dungu’s research interest is cardiomyopathy and he was awarded a BHF Clinical 
    Research Fellowship in 2009, culminating in the award of a PhD degree in ATTR cardiac amyloidosis. The research project produced several papers and over 30 abstracts. 
    He has presented at major international cardiology conferences in Europe and North 
    America, and co-authored publications in the top 3 medical journals NEJM, Lancet and JAMA.

    Prof Dr med Carsten Tschöpe is a distinguished cardiologist and researcher, leading the 
    Clinical Cardiomyopathy Unit at the Deutsches Herzzentrum der Charité (DHZC) and 
    the Translational Cardiovascular Unit at the Berlin Institute of Health (BIH) and BCRT. 
    As a University Professor of Medicine and Cardiology, his expertise spans intensive 
    and interventional cardiology, with a prominent focus on heart failure, myocarditis, 
    and cardiomyopathies. With over 550 publications, he has made a lasting impact on 
    immunocardiology. As a board member of the Heart Failure Association (HFA) and 
    Chair of the ESC Working Group on Myocardial and Pericardial Diseases, he plays a 
    pivotal role in shaping the future of cardiovascular research and treatment.

You may also be interested in:

Navigating ATTR-CM Diagnosis
Beyonttra®▼ (acoramidis) | Explore resources on Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
PP-PF-CAR-GB-0060, October 2025
Beyonttra®▼ (acoramidis) - Overview
About Beyonttra
PP-BEY-GB-0001, May 2025
HF-IMPACT Hub
Explore Resources and Events Focussed on Improving Management and Prognosis Through Advance Cardiac Training
PP-BEY-GB-0074, October 2025
CV Summit 2025 - Highlights
Register Your Interest for 2026 Here
PP-BEY-GB-0007, November 2025
Register for BayerPRO - Beyonttra

Register for BayerPRO

Stay up to date on future events and webinars posted by registering to BayerPRO here.

Register Now

Abbreviation:

ATTR-CM, Transthyretin Amyloid Cardiomyopathy.
PP-BEY-GB-0085 | November 2025